Clinical trials: Breast Imaging
Breast Cancer
PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
The purpose of this study is to learn more about how a new study agent works inside the body. The study agent is a protein called 64Cu-trastuzumab.
- Trial name
- Cu-64 HER2+ (NCT00605397)
- Testing
- PET Imaging With Cu-64 Labeled Trastuzumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery
The purpose of this study is to compare the diagnostic accuracy of breast magnetic resonance imaging (MRI) and contrast enhanced digital mammography (CEDM) in assessing the residual disease extent in patients who have completed…
- Trial name
- NCT03070340
- Testing
- Breast Magnetic Resonance Imaging (MRI), Contrast Enhanced Mammography (CEDM)
- Where
- 5 sites in United States
- Volunteers
- 125 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Suspicious Breast Lesion for Which Biopsy is Scheduled
Use of Low-dose Molecular Breast Imaging for the Detection of Small Breast Lesions
The purpose of this study is to show that improvements in the molecular breast imaging (MBI) technology will allow reduction of the administered dose of Tc-99m sestamibi while maintaining a sensitivity of 90% for tumor detection.
- Trial name
- Lowdoseprebx (NCT01285440)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Mayo Clinic
Breast Cancer
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer
The investigators plan to conduct a 68Ga-DOTA-dPNE PET/CT imaging study in breast cancer patients to observe the binding of the tracer to tumor lesions and evaluate CD73 expression.
- Trial name
- NCT06411678
- Testing
- 68GA-DOTA-dPNE
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Ductal Carcinoma In Situ, Invasive Breast Cancer
Digital Breast Tomosynthesis Versus Contrast Enhanced Magnetic Resonance Imaging (MRI) for Breast Cancer Staging
The primary objective of this study is to compare the diagnostic accuracy of Digital Breast Tomosynthesis (DBT) versus that of Contrast Enhanced Magnetic Resonance Imaging (CEMRI) in determining the size of breast cancer…
- Trial name
- NCT01060085
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Molecular Imaging
Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue
The primary objective of this study is to determine if exercise, fasting, or eating prior to the molecular breast imaging study will have an effect on the uptake of the tracer in the breast tissue.
- Trial name
- NCT01944215
- Testing
- Meal, Exercise, Sestamibi
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer, Sentinel Lymph Node Biopsy (SLNB)
Finding Sentinel Lymph Nodes During Mastectomy Using Indocyanine Green (INIGMA Study)
This pilot study evaluates the diagnostic value of indocyanine green (ICG) fluorescence for sentinel lymph node biopsy (SLNB) performed through the mastectomy incision in breast cancer patients.
- Conditions
- Breast Cancer, Sentinel Lymph Node Biopsy (SLNB), Sentinel Lymph Node Detection, Sentinel Lymph Node
- Trial name
- INIGMA (NCT07362485)
- Testing
- Indocyanine green (ICG)-fluorescence guided sentinel lymph node biopsy
- Where
- 2 sites in Netherlands
- Volunteers
- 90 people
- Sponsor
- Isabelle Henskens
Breast Cancer, TNBC - Triple-Negative Breast Cancer
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor（ER）-positive tumors .
- Conditions
- Breast Cancer, TNBC - Triple-Negative Breast Cancer, Estrogen-receptor-negative Breast Cancer
- Trial name
- NCT05541367
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tongji Hospital
Breast Cancer
Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT
Patients with known or suspected, in the opinion of an investigator, primary or metastatic breast cancer may be eligible for this study. Up to 45 evaluable participants may undergo study imaging in this protocol.
- Trial name
- FTT 2 (NCT03846167)
- Testing
- Imaging Drug FluorThanatrace (FTT)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Breast Cancer Metastatic
HER2-PET Imaging in HER2-low Breast Cancers
A strategy to target the oncogenic receptor HER2 using a version of the anti-HER2 therapeutic antibody trastuzumab coupled to desferrioxamine (DFO) and radiolabeled with zirconium-89 ([89Zr]-DFO-trastuzumab) has been successfully…
- Trial name
- NCT06732336
- Testing
- 89Zr-trastuzumab
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Breast Cancer
Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer
The purpose of this study is to investigate the safety and imaging ability of 111In-DAC when used with planar and SPECT imaging for the detection of breast cancer.
- Trial name
- NCT00040430
- Testing
- 111In-DAC, Diagnostic
- Where
- 2 sites in United States
- Sponsor
- Copharos
Breast Cancer, Metastatic Cancer
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help doctors find CNS metastases and plan treatment.
- Trial name
- NCT00398437
- Testing
- trastuzumab, chemotherapy, magnetic resonance imaging
- Where
- 3 sites in Belgium
- Volunteers
- 96 people
- Sponsor
- Jules Bordet Institute
Breast Cancer
Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Breast Cancer
The objective of this study is to demonstrate the efficacy and response of novel Magnetic Resonance Imaging (MRI)-guided ultrasound stimulated microbubble treatment to enhance radiation effects in humans receiving external beam…
- Trial name
- NCT06185972
- Testing
- Definity, Sonalleve Focused Ultrasound Device
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Sunnybrook Health Sciences Centre
Hereditary Breast and Ovarian Cancer Syndrome
Women at Risk of Breast Cancer and OLFM4
Does the olfactomédine provide an help to limit the number of false positives in the overall imaging balance and limit the number of unnecessary biopsies?
- Trial name
- NCT02653105
- Testing
- OLFM4
- Where
- 4 sites in France
- Volunteers
- 150 people
- Sponsor
- Institut Cancerologie de l'Ouest
HER2-positive Breast Cancer
MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA)
This Phase 1b/2 study is designed as an open-label, multicenter, 3 group, interventional study in which Phase 1b will evaluate the pharmacokinetics (PK) of MSH2IA and Phase 2 will confirm lowest effective dose as well as evaluate…
- Trial name
- NCT07885683
- Testing
- The MagSense® HER2 Imaging Agent (MSH2IA)
- Volunteers
- 70 people
- Sponsor
- Imagion Biosystems, Inc.
Breast - Female
Feasibility of Imaging Breast Implants With a Transmission-based Microwave Scanner
The goal of this clinical trial is to assess whether microwave scans can depict the presence of implants in the breast in women with existing breast implants that were surgically placed at least 6 months ago.
- Trial name
- NCT07487792
- Testing
- WVI-MIS-03-2025
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Calgary
Breast Cancer
The Use of 3D Surface Imaging in the Objective Assessment of Breast Conserving Therapy
3D surface imaging has been used in the objective evaluation of cosmetic outcome of oncoplastic procedures such as breast reconstruction and lipofilling, however there is only one article published relating to Breast Conserving…
- Trial name
- 3DBCT (NCT02304614)
- Testing
- 3D surface imaging using a non portable and portable camera, Patient reported outcome measure (PROM): BREAST-Q, 2D photography
- Where
- United Kingdom
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer Diagnosis, Positron Emission Tomography
Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis
The application of FCH PET in breast cancer diagnosis has not been reported. We hypothesize that FCH reveals choline metabolic profiles of breast cancers, and shows the similar pathophysiological mechanism to choline on proton…
- Conditions
- Breast Cancer Diagnosis, Positron Emission Tomography, Magnetic Resonance Imaging
- Trial name
- NCT01956409
- Testing
- 18F-FCH, Magnevist
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer
BIOPSY SCANNER LLTECH© Technology for Diagnosis of Breast Cancer
Breast cancer is a frequent pathology and the speed of initial diagnosis makes it possible to improve the course of care and to reduce the anxiety of the patients.
- Trial name
- LLTECHBreast (NCT04292821)
- Where
- France
- Volunteers
- 217 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer
3-Dimensional Form and Soft Tissue Biomechanics of the Breast
The goal of this clinical research study is to characterize the 3-dimensional form and mechanical properties of the breast. Researchers want to do this in order to develop new high technology tools for improving the diagnosis and…
- Trial name
- NCT00502814
- Testing
- 3-D Optical Surface Scan, Mechanical Testing, Cutaneous Ultrasound
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center